Yupelri generic
Yupelri is an inhalable solution owned by Mylan Ireland Ltd. The drug received its first market authorization on 09 November, 2018. Yupelri's active ingredient is revefenacin and it has a total of 18 patents.
When will Yupelri generic be available?
The generic version of Yupelri may become available after 23 October, 2039. This release date corresponds with the expiration of the last Yupelri patent. As of this date, no Yupelri patents have expired, and the earliest possible date for Para IV challenge filings is 2022-11-09.
Yupelri uses
Yupelri, containing the active ingredient revefenacin, is commonly used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Yupelri patent expiration
Yupelri has a total of 18 patents protecting it. The last patent, US11484531, is set to expire on 23 October 2039. This will potentially pave the way for a Yupelri generic release. Below are the details of the patent: